October 21, 2026
Muna Therapeutics Announces Positive Phase 1 Results Supporting Potential of Oral Small-Molecule TREM2 Modulator, MNA-001, in Alzheimer’s Disease

COPENHAGEN, Denmark and BOSTON, U.S., October 21, 2026 – Muna Therapeutics (Muna), a clinical-stage biotechnology company developing innovative treatments for neurodegenerative diseases, today announced positive results from its Phase 1 study of MNA-001, a potent, selective, orally administered small-molecule modulator of triggering receptor expressed on myeloid cells 2 (TREM2) that support the treatment’s potential in early Alzheimer’s disease. The study demonstrated favorable safety and tolerability, strong cerebrospinal fluid (CSF) exposure, and dose-dependent target engagement in younger and elderly volunteers.

Read More
June 30, 2026
Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances

COPENHAGEN, Denmark & BOSTON, June 30, 2026 – Muna Therapeutics (Muna), a biotechnology company pioneering novel therapeutics for neurodegenerative diseases, today announced a CEO transition. Rita Balice-Gordon, Ph.D., Muna’s founding CSO and CEO since 2021, will step down and join the Company’s Board of Directors. Michel Detheux, Ph.D., a seasoned biotech entrepreneur and former President and CEO of iTeos Therapeutics (NASDAQ: ITOS), has been appointed CEO, effective June 29, 2026.

Read More
June 4, 2026
Muna Therapeutics Announces Nature Medicine Publication Validating Microglial State Transitions as Key Drivers of Alzheimer’s

COPENHAGEN, Denmark and BOSTON, U.S., June 4, 2026 – Muna Therapeutics, a clinical-stage biotechnology company pioneering a new era of drug discovery for neurodegenerative diseases, today announced the publication of a seminal study in Nature Medicine: “Human microglial transitions at the Aβ–Tau inflection point associate with divergent pathways to dementia and resilience.”

Read More